Novartis Korea, Handok holds symposium for Galvusmet

Published: 2010-02-26 06:56:00

Updated: 2010-02-26 06:56:00

Novartis Korea and Handok Pharm said on February 20 that it has held a launching symposium for Galvusmet, a combination drug consisting of 850–1000 mg metformin and 50 mg of the DPP-4 inhibitor vildagliptin, while Galvus consists of 50 mg vildagliptin.

In treatment-naive patients, combinations...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK